Key Highlights

  • MDBH shares trading down 27.62% to $1.31, a penny stock.
  • The company reported a net loss of about $16.1 million for the first half of 2026.
  • Net cash, current Assets and marketable securities stood near $12.1 million at the end of the second quarter.
  • Operating cash used was $5.5 million in the first half, with fixed operating expenses near $5 million.
  • Trailing twelve-month Revenue was $5.48 million, up 135.5%, according to a data provider.

No Announcement Found for the Drop in MDB Capital Holdings Shares

MDB Capital Holdings (NASDAQ:MDBH) shares are trading down 27.62% today, and no company-specific press release or filing explaining the decline was identified. The prior close works out to roughly $1.81 based on today's price and move.

The company runs what it calls a public venture platform. Through its subsidiaries it operates a broker-dealer that handles securities offerings and research, offers intellectual property services through PatentVest, and is building a small-molecule senescence platform in its Technology Development segment.

First-Half Net Loss of $16.1 Million and Non-Cash Charges

In its second-quarter update on August 13, MDB reported a net loss of about $16.1 million for the first half of 2026, including $9.3 million in the second quarter. Roughly $5 million came from revaluing Investment securities and another $5 million from stock-based compensation tied to 2022 grants.

Operating costs were stable across the period, based on the update. Fixed operating expenses were flat at about $5 million for the half. The company also recorded a $641,000 Impairment on its stake in eXoZymes and absorbed a $3.1 million share of that investee's losses.

A data provider listed trailing revenue of $5.48 million, Net Income of negative $22.46 million and a loss of $2.20 per share as of early September.

Cash Burn, Share Count and a Stock Now Far Below Its 52-Week Range

Operating activities used $5.5 million of cash in the first half. Management put net cash, current assets and marketable securities near $12.1 million at quarter-end and said it intends to keep the platform lean and avoid further dilution at the parent level.

With about 10.44 million shares outstanding, the current price implies a Market Value near $13.7 million, which is a rough estimate. The 52-week range as of early September was $2.45 to $4.80, so today's price is well below that band.

Recent activity included a September Partnership between PatentVest and BioNTX on intellectual property diligence, along with acting as sole bookrunner on a $20 million Buda Juice IPO, partnering on a $15 million Ticketplus IPO and supporting a $5.9 million eXoZymes offering. The company also said that more aggressive IPO plans were deferred because microcap markets remain challenging.

PatentVest Spinout and Asset Monetization Plans Set the Agenda

Net losses of this size relative to the company's liquid resources are a central point for holders, since the platform's fixed costs continue while revenue depends on deal timing. Management has said it plans to monetize four core assets, including a possible spinout of PatentVest as a separate publicly traded AI-focused intellectual property law firm, and that it is in advanced discussions with potential strategic partners. Investors will watch for the next quarterly update and for any filing that clarifies what drove today's decline.